Search Results - "Treue, D"

Novel methods for in vitro modeling of pancreatic cancer reveal important aspects for successful primary cell culture by Ehlen, L, Arndt, J, Treue, D, Bischoff, P, Loch, F N, Hahn, E M, Kotsch, K, Klauschen, F, Beyer, K, Margonis, G A, Kreis, M E, Kamphues, C

“…Pancreatic cancer remains a fatal disease. Experimental systems are needed for personalized treatment strategies, drug testing and to further understand tumor…”
Get full text

Cancer beyond organ and tissue specificity: Next‐generation‐sequencing gene mutation data reveal complex genetic similarities across major cancers by Heim, D., Budczies, J., Stenzinger, A., Treue, D., Hufnagl, P., Denkert, C., Dietel, M., Klauschen, F.

“…Cancer medicine relies on the paradigm that cancer is an organ‐ and tissue‐specific disease, which is the basis for classifying tumors. With the extensive…”
Get full text

Abstract PD5-05: Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial by Sinn, BV, Loibl, S, Karn, T, Untch, M, Kunze, CA, Weber, KE, Treue, D, Wagner, K, Hanusch, CA, Klauschen, F, Fasching, PA, Huober, J, Zahm, D-M, Jackisch, C, Thomalla, J, Blohmer, J-U, van Mackelenbergh, M, Rhiem, K, Felder, B, von Minckwitz, G, Burchardi, N, Schneeweiss, A, Denkert, C

“…Background In the GeparNuevo trial, the PD-L1 inhibitor durvalumab increased the rate of pathologic complete response (pCR; ypT0 ypN0) in triple-negative…”
Get full text

Abstract PD2-07: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)– Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial by Loibl, S, Sinn, BV, Karn, T, Untch, M, Treue, D, Sinn, H-P, Weber, KE, Hanusch, CA, Fasching, PA, Huober, J, Zahm, D-M, Jackisch, C, Thomalla, J, Blohmer, J-U, Marmé, F, Klauschen, F, Rhiem, K, Felder, B, von Minckwitz, G, Burchardi, N, Schneeweiss, A, Denkert, C

“…Background: The GeparNuevo trial showed a numerical increase in the pCR rate to 53% vs 44%; p=0.281 compared to placebo in TNBC with the addition of the…”
Get full text

TP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: Results from the CONKO-001 study by Sinn, M., Budczies, J., Damm, F., Lohneis, P., Schmuck, R., Treue, D., Striefler, J.K., Bahra, M., Pelzer, U., Jühling, A., Bläker, H., Bischoff, S., Oettle, H., Denkert, C., Riess, H., Sinn, B.

Get full text

Effect of YB-1 on the Regulation of Micro RNA Expression in Drug-sensitive and Drug-resistant Gastric Carcinoma Cells by BELIAN, Elisa, KURUCZ, Reka, TREUE, Denise, LAGE, Hermann

“…The multifunctional Y-Box protein 1 (YB-1) exerts positive and negative regulatory effects on gene expression by different mechanisms. Since transcription can…”
Get full text

Regulation of mRNA Expression in Drug-sensitive and Drug-resistant Gastric Carcinoma Cells Is Independent of YB-1 Expression by KURUCZ, Reka, BELIAN, Elisa, TREUE, Denise, LAGE, Hermann

“…Y-Box protein 1 (YB-1) is a multifunctional cellular protein expressed in a range of mammalian cells, including human cancer cells. It is involved in the…”
Get full text